Home > Academic Announcements > (Nov. 20) Frontiers in Pharmaceutical Science Lecture Series - No. 165

(Nov. 20) Frontiers in Pharmaceutical Science Lecture Series - No. 165

Last updated :2013-11-12

Topic: Selective Targeting of Hypoxic Cancer Cells with the Hypoxia-Activated Prodrug TH-302: Preclinical and Clinical Studies
Speaker: DUAN Jianxin
, Ph.D., Vice President in R&D, Threshold.
Chair: Prof. WANG Zhong, School of Pharmaceutical Science, Sun Yat-sen University
Time: 2:30 PM, Wednesday, November 20, 2013
Venue: 125 Lecture Hall, School of Pharmaceutical Science, East Campus, SYSU


Introduction of the Speaker:

Dr. DUAN Jianxin graduated from Shanghai Institute of Organic Chemistry with a MS in 1992, and completed his PhD in 2001 at the University of Florida. He joined Threshold Pharmaceuticals Inc. in 2003 as staff scientist, senior staff scientist, Director, Senior Director, now as Threshold Fellow, the highest level of R&D at Threshold Pharmaceuticals. Dr. Duan’s major interest is anticancer drug discovery. One of Duan’s major achievements is discovering the investigational drug TH-302, which helped Threshold Pharmaceuticals guarantee its future. Merck Serono has so far provided $100 million to the company and agreed to share 70% of the cost of Phase III clinical trials as well as additional research and tests on the compound, which appears to be effective against several types of cancers. Total payments from Merck Serono could reach $550 million if ongoing phase III trials result in a market launch.

All are welcome to the lecture!